11-12-2025 21:07 via medpagetoday.com

ADC Post-Endocrine Therapy Misses Mark in Advanced Breast Cancer Trial

(MedPage Today) -- SAN ANTONIO--The antibody-drug conjugate (ADC) sacituzumab govitecan (Trodelvy) failed to outperform chemotherapy as first treatment after endocrine therapy for metastatic hormone receptor-positive/HER2-negative breast cancer...
Read more »

Medical news



Novel Oral Antibiotic Matches Standard Option for Urogenital Gonorrhea
First At-Home Device Approved for Depression
Senate Rejects Extension of Obamacare Subsidies
Senators Urge More Localized Use of Donor Organs
GLP-1 Drugs Linked to Lower Epilepsy Risk in Diabetes Patients
FDA Approves New Type of Antibiotic for Gonorrhea, First in Decades
RFK Jr.’s Former Group Urges FDA to Revoke COVID Vax Licenses
Florida Sues Medical Groups Over Youth Gender-Affirming Care
Uterine Fibroids Point to Risk of Heart Disease Down the Line
RFK Jr.'s Viral Pull-Ups; Docs Denounce ACIP's Hep B Vote; 'Don't Pee!'
Blood Clots in Ulcerative Colitis; AI Tool for MASH; Stomach Cancer Screening?
FDA Proposes Allowing New Sunscreen Ingredient
Expand Labeling for Testosterone Replacement Therapy, FDA Panel Says
RFK Jr. Tops This Year's Shkreli Awards
Desktop versie